文献速递外周动脉疾病

IN.PACT药物涂层球囊汇总影像与倾向匹配队列报告

Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts.
PubMed 文献 · J Vasc Surg · 2019-01-01

该研究汇总两项随机对照试验和两项单臂前瞻性研究的个体数据,比较IN.PACT Admiral药物涂层球囊(DCB)与经皮腔内血管成形术(PTA)治疗股腘动脉病变的安全性和有效性。共纳入DCB组926例、PTA组143例,并进行倾向匹配分析(DCB 466例 vs PTA 136例)。12个月时DCB组在主要通畅率、免于临床驱动靶病变血运重建(CD-TLR)和主要安全复合终点上均显著优于PTA。

要点

  • 12个月DCB组主要通畅率88.8% vs PTA 53.9%(P<.001)。
  • 倾向匹配后DCB组主要通畅率90.5% vs PTA 53.8%(P<.001)。
  • DCB组免于CD-TLR和主要安全复合终点均显著优于PTA。

核心结论

  • IN.PACT Admiral DCB在12个月时主要通畅率、免于CD-TLR和主要安全复合终点均显著优于PTA。

研究设计与样本

  • 个体水平汇总分析,纳入两项随机对照试验和两项单臂前瞻性研究。
  • DCB组926例,PTA组143例;倾向匹配分析DCB 466例 vs PTA 136例。
  • 终点由超声核心实验室和临床事件委员会裁定。

主要发现

  • 12个月DCB vs PTA主要通畅率88.8% vs 53.9%(P<.001)。
  • 12个月DCB vs PTA免于CD-TLR 94.3% vs 80.2%(P<.001)。
  • 12个月DCB vs PTA主要安全复合终点94.1% vs 78.0%(P<.001)。
  • 倾向匹配后DCB vs PTA主要通畅率90.5% vs 53.8%(P<.001)。
  • 倾向匹配后DCB vs PTA免于CD-TLR 96.9% vs 80.7%(P<.001),主要安全复合终点96.3% vs 78.4%(P<.001)。

临床怎么用

  • 对于股腘动脉病变,DCB在12个月的通畅率和安全性上优于PTA。
  • 倾向匹配和亚组分析(包括临时支架)中DCB优势持续存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Randomized controlled trials have shown that drug-coated balloons (DCBs) provide superior results compared with percutaneous transluminal angioplasty (PTA) for the treatment of femoropopliteal artery disease. However, these trials have generally included short lesions, few occlusions, and small sample sizes. The present study was an individual-level pooled analysis of duplex ultrasonography (DUS) core laboratory-adjudicated and clinical events committee-adjudicated IN.PACT Admiral DCB subjects across two randomized controlled trials and two single-arm prospective studies to characterize the safety and effectiveness of DCB compared with PTA. METHODS: The subjects were treated with DCB (n = 926) or PTA (n = 143). The end points through 12 months included DUS core laboratory-adjudicated primary patency and clinically driven target lesion revascularization (CD-TLR) using Kaplan-Meier estimates and primary safety using proportions. A propensity-matched analysis of DCB (n = 466) to PTA (n = 136) was conducted to address confounders. RESULTS: At 12 months, DCB compared with PTA had significantly greater primary patency (88.8% vs 53.9%; P < .001), freedom from CD-TLR (94.3% vs 80.2%; P < .001), and better primary safety composite end point (94.1% vs 78.0%; P < .001). After propensity-matched analysis, DCB remained superior to PTA at 12 months for primary patency (90.5% vs 53.8%; P < .001), freedom from CD-TLR (96.9% vs 80.7%; P < .001), and the primary safety composite end point (96.3% vs 78.4%; P < .001). Across multiple prespecified subgroup analyses, including provisional stenting, DCB remained persistently superior to PTA. CONCLUSIONS: In the largest, DUS core laboratory-adjudicated, multiethnic, pooled DCB series to date, the IN.PACT Admiral DCB demonstrated significantly greater primary patency, freedom from CD-TLR, and better composite safety at 12 months compared with PTA.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shishehbor MH, Schneider PA, Zeller T, et al. Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts. J Vasc Surg. 2019. PMID: 31543165. doi:10.1016/j.jvs.2019.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。